Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
jRCT2051240131Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of LY3848575 in Neuralgia and distal sensorimotor polyneuropathy (DSPN) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean change from baseline in Average Pain Intensity Numeric Rating Scale (API-NRS). Started Oct 2024; status: active, not recruiting.
02
Drugs
LY3848575
03
Conditions
Neuralgiadistal sensorimotor polyneuropathy (DSPN)
Beyond the preview
Go deeper on jRCT2051240131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240131.